Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab in HER2-positive metastatic gastric cancer
NCT01774786Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2013
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and gastroesophageal junction cancer comparing Pertuzumab Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival up to 70 months. Started Jun 2013; status: completed.
02
Drugs
pertuzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01774786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01774786.